207 related articles for article (PubMed ID: 16865780)
1. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
3. Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats.
Hussein O; Grosovski M; Lasri E; Svalb S; Ravid U; Assy N
World J Gastroenterol; 2007 Jan; 13(3):361-8. PubMed ID: 17230603
[TBL] [Abstract][Full Text] [Related]
4. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
6. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
[TBL] [Abstract][Full Text] [Related]
7. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
[TBL] [Abstract][Full Text] [Related]
8. Effect of silybin on high-fat-induced fatty liver in rats.
Yao J; Zhi M; Minhu C
Braz J Med Biol Res; 2011 Jul; 44(7):652-9. PubMed ID: 21755261
[TBL] [Abstract][Full Text] [Related]
9. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
Huang Y; Fu JF; Shi HB; Liu LR
Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
[TBL] [Abstract][Full Text] [Related]
10. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
13. Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.
Qiang G; Zhang L; Yang X; Xuan Q; Shi L; Zhang H; Chen B; Li X; Zu M; Zhou D; Guo J; Yang H; Du G
Eur J Pharmacol; 2012 Jun; 685(1-3):156-64. PubMed ID: 22546234
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats.
Wei Y; Clark SE; Morris EM; Thyfault JP; Uptergrove GM; Whaley-Connell AT; Ferrario CM; Sowers JR; Ibdah JA
J Hepatol; 2008 Sep; 49(3):417-28. PubMed ID: 18486983
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis.
Tahan V; Eren F; Avsar E; Yavuz D; Yuksel M; Emekli E; Imeryuz N; Celikel C; Uzun H; Haklar G; Tozun N
Dig Dis Sci; 2007 Dec; 52(12):3465-72. PubMed ID: 17436085
[TBL] [Abstract][Full Text] [Related]
16. Hepatic effects of rosiglitazone in rats with the metabolic syndrome.
Ackerman Z; Oron-Herman M; Pappo O; Peleg E; Safadi R; Schmilovitz-Weiss H; Grozovski M
Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):663-8. PubMed ID: 20210788
[TBL] [Abstract][Full Text] [Related]
17. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Qi Z; Xue J; Zhang Y; Wang H; Xie M
Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease.
Wang HN; Wang YR; Liu GQ; Liu Z; Wu PX; Wei XL; Hong TP
World J Gastroenterol; 2008 Dec; 14(47):7240-6. PubMed ID: 19084941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
